Pathway Health to get a tech upgrade through Virtual Health partnership

Pathway Health and Virtual Health, a population health management technology provider, have entered into a partnership that will provide Pathway with strategic consulting services to improve technology and payment models.

Pathway, based in White Bear Lake, Minnesota, offers consulting services in areas like executive searches, interim management and education. Through this partnership, Pathway will have access to Virtual Health’s platform that will provide its clients with data, tools and business intelligence, the companies said in a joint statement.

“This collaboration equips Pathway Health’s post-acute care experts with the most comprehensive technology in the marketplace as they work with cross-functional teams to enhance collaboration, quality of care, and patient outcomes,” said Adam Sabloff, CEO at Virtual Health, in the statement.

The partnership will help provide Pathway’s clients with quality and disease-state management processes, decrease hospital readmission rates and make facilities more efficient overall.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.